Will prior novel hormonal therapy affect when/how you use olaparib plus abiraterone for patients with BRCA-mutated metastatic castration resistant prostate cancer?
Community PollStarted
How does prior exposure to novel androgen receptor signaling inhibitors (ARSIs) impact your use of PARPi in patients with BRCA+/HRRm prostate cancer?
51 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Duke University School of Medicine
Answered on
Yes, there is no clear data at this time that an AR/PARP inhibitor combination prolongs rPFS or OS in men with mCRPC who have progressed on a prior potent AR inhibitor, as largely these men were excluded or not included in PROpel, MAGNITUDE, or TALAPRO-2. For patients who develop mCRPC but have not ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · The University of Texas Health Science Center at San Antonio
Answered on
PARPi/ARSI combinations have consistently been shown to prolong progression free survival over ARSIs alone. (1, 2, 3) There are a number of combinations now available including olaparib/abiraterone, niraparib/abiraterone, talazoparib/enzalutamide. The overall survival data is immature in each of the...
Join for free or sign in to see the full answer